The DOI matches its Crossref record; 111 of the 111 references it cites were found in a registry or an index; 24 of the 147 sources its claims cite were checked for support.
RAS Mutations in Advanced Colorectal Cancer: Mechanisms, Clinical Implications, and Novel Therapeutic Approaches
Open accessAbstract
Colorectal cancer (CRC) remains a leading cause of cancer-related mortality globally, posing significant treatment challenges, particularly in its metastatic form (mCRC). This review comprehensively examines the pivotal role of RAS mutations, specifically KRAS and NRAS, which are detected in approximately 40–45% of mCRC cases, and their impact on treatment decisions and patient outcomes. We assess the effectiveness of standard treatments within the RAS mutant population, highlighting the challenges and limitations these therapies face. Recent advancements in targeted therapies, particularly the focus on novel agents such as KRAS G12C inhibitors, including sotorasib and adagrasib, have shown promising efficacy in overcoming resistance to conventional treatments. Furthermore, this review discusses future directions, emphasizing the need for research into non-RAS targets to address the complexities of resistance mechanisms and improve therapeutic outcomes. This review aims to provide a detailed overview of the current treatments and innovative approaches, supporting the development of personalized management strategies for patients with mCRC.
Overview
CoChat Summary
TL;DR
This review summarizes how RAS mutations, found in approximately 40–45% of metastatic colorectal cancer (mCRC), drive resistance to anti-EGFR therapies and shape prognosis. It highlights retained activity of anti-angiogenic agents and emerging KRAS G12C inhibitor combinations, alongside investigational strategies for other RAS variants.
Key findings
- RAS mutations (mostly KRAS/NRAS) are detected in approximately 40–45% of mCRC; anti-EGFR agents should not be used first-line in KRAS-mutant tumors, and extended RAS testing is needed before targeted therapy.
- In CodeBreaK-300, sotorasib 960 mg plus panitumumab achieved mPFS 5.6 months and ORR 26%, versus mPFS 3.9 months and ORR 6% for sotorasib 240 mg; the control arm had no objective responses. In KRYSTAL-1, adagrasib monotherapy ORR was 19% (95% CI 8–33) and adagrasib plus cetuximab ORR was 46% (95% CI 28–66); NCCN recommends these combinations for pretreated KRAS G12C mCRC.
- Anti-angiogenic agents retain efficacy in RAS-mutant tumors: ML18147 showed no significant KRAS interaction for PFS (p = 0.443) or OS (p = 0.126); RAISE showed significant mPFS improvement in RAS-mutant patients (p = 0.021); a meta-analysis of 14 phase III trials found OS interaction p = 0.003 (RAS WT HR 0.78 vs. mutant HR 0.91).
- Immunotherapy findings differ by MSI status: in CheckMate 142, ORR was 41% in RAS/BRAF wild-type versus 27% in RAS-mutant MSI-H mCRC; in MSS MAYA, temozolomide followed by nivolumab–ipilimumab gave mPFS 7.1 months (95% CI 5.6–8.4), with 72% RAS-mutant patients and no significant ORR difference between RAS mutant and wild-type (p = 0.660).
Methods
- Narrative review; literature selection described in the Introduction using PubMed, Scopus, and ClinicalTrials.gov, with keywords including “RAS mutation,” “colorectal cancer,” “KRAS,” and “targeted therapy.”
- Timeframe January 2010 to March 2025; both peer-reviewed original articles and clinical trial results were considered.
- No formal systematic review protocol, risk-of-bias assessment, or quantitative meta-analysis is reported.
Limitations
- The paper does not state a formal limitations section; it notes future challenges including equitable access to biomarker testing, cost-related barriers, and expanding molecular profiling infrastructure across diverse clinical settings.
- Evident from the text: this is a narrative review with a brief literature-selection description, no reported systematic risk-of-bias assessment, and no quantitative synthesis, so conclusions depend on the selected published trials and may not be exhaustive.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
15 Valid · 6 Not valid · 110 Not checked · 18 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Approximately 45% of patients diagnosed with mCRC have KRAS mutations, and the presence of mutations is important both in terms of prognosis [9,10].”
§ RAS Mutations in Advanced Colorectal Cancer: Mechanisms, Clinical Implications, and Novel Therapeutic Approaches > 1. Introduction > 1.2. Prognostic and Predictive Role of RAS Mutation in Patients Diagnosed with mCRC
What the sources say
- Disputedcites [9] Modest, 2016, Outcome according to KRAS-, NRAS-and BRAF-mutation as well as KRAS mutation variants: Pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group, Ann. Oncol. sourceExperimental — accuracy not yet measured
The mutations section reports KRAS mutations in 462 of 1,239 analyzed mCRC tumors (37.3%), not approximately 45%. The introduction’s approximately 50% figure refers to KRAS and NRAS combined, not KRAS alone. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
- Disputedcites [10] Zocche, D.M., Ramirez, C., Fontao, F.M., Costa, L.D., and Redal, M.A. (2015). Global impact of KRAS mutation patterns in FOLFOX treated metastatic colorectal cancer. Front. Genet., 6. sourceExperimental — accuracy not yet measured
The Results (Patient Characteristics) report KRAS mutations in 48 of 148 patients with metastatic colorectal cancer (32%), not approximately 45%. The Introduction gives a broader colorectal-cancer estimate of 30–40%, which also does not support 45%. (LLM, conf=0.87)
Checked by a reasoning model — may be wrong.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
Every source the paper cites for this claim was checked and supports it.
In the paper
“In studies evaluating the addition of bevacizumab to chemotherapy agents, the addition of bevacizumab contributes to PFS, regardless of KRAS mutation status [17,18].”
§ RAS Mutations in Advanced Colorectal Cancer: Mechanisms, Clinical Implications, and Novel Therapeutic Approaches > 1. Introduction > 1.2. Prognostic and Predictive Role of RAS Mutation in Patients Diagnosed with mCRC
What the sources say
- Supportedcites [17] Price, 2015, Correlation of extended RAS and PIK3CA gene mutation status with outcomes from the phase III AGITG MAX STUDY involving capecitabine alone or in combination with bevacizumab plus or minus mitomycin C in advanced colorectal cancer, Br. J. Cancer source
The Results (Progression-free survival) report longer PFS with bevacizumab plus capecitabine than with capecitabine alone in both RAS-mutant and RAS-wild-type groups, with no significant treatment interaction by RAS status. The Discussion also states that KRAS exon 2 mutation status was not predictive of bevacizumab effect. The paper provides direct evidence for this claim in advanced colorectal cancer treated with capecitabine. (LLM, conf=0.92)
- Supportedcites [18] Hurwitz, 2009, The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of K-ras mutation status: Analysis of a phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer, Oncologist source
The Predictive Value of K-ras Mutations section reports significantly longer progression-free survival with bevacizumab added to IFL chemotherapy in both wild-type and mutant K-ras groups. The finding is from previously untreated metastatic colorectal cancer patients receiving this specific chemotherapy regimen; the copy does not provide a page number. (LLM, conf=0.93)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“The interaction test by KRAS status showed no statistically significant difference in bevacizumab efficacy between KRAS mutant and wild-type tumors, with p = 0.443 for PFS and p = 0.126 for OS [23].”
§ RAS Mutations in Advanced Colorectal Cancer: Mechanisms, Clinical Implications, and Novel Therapeutic Approaches > 1. Introduction > 1.2. Prognostic and Predictive Role of RAS Mutation in Patients Diagnosed with mCRC
What the sources say
- Could not verifycites [23] Lenz, 2015, Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer, J. Clin. Oncol. sourceExperimental — accuracy not yet measured
The Efficacy According to RAS Mutation Status and Discussion passages concern cetuximab in the CRYSTAL study, not bevacizumab in ML18147. Searches for ML18147, bevacizumab, the KRAS interaction test, and the stated P values found no passage addressing the claim in our copy; page numbers were unavailable. (LLM, conf=0.78)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The results showed a significant advantage for upfront FOLFOXIRI plus bevacizumab in terms of PFS2 with an mPFS2 of 19.1 months vs. 16.4 months for the comparator arm (HR 0.74, p < 0.001).”
§ RAS Mutations in Advanced Colorectal Cancer: Mechanisms, Clinical Implications, and Novel Therapeutic Approaches > 1. Introduction > 1.2. Prognostic and Predictive Role of RAS Mutation in Patients Diagnosed with mCRC
What the sources say
- Partly supportedcites [33] Cremolini, 2020, Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): A multicentre, open-label, phase 3, randomised, controlled trial, Lancet Oncol. sourceExperimental — accuracy not yet measured
The Results section of our copy confirms a significant PFS2 advantage for upfront FOLFOXIRI plus bevacizumab: median PFS2 19•2 months (95% CI 17•3-21•4) in the experimental group versus 16•4 months (15•1-17•5) in the control group, HR 0•74 (0•63-0•88), p<0•001 (figure 2A). The control median (16.4), the HR (0.74) and the p-value (p<0.001) match the claim exactly, but the experimental median is 19.2 months in the source, not the 19.1 months the citing sentence reports. No other part of the attribution is unsupported (PFS2 is indeed the trial's primary endpoint, per section 9.1). (LLM, conf=0.70)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Furthermore, the addition of anti-angiogenic treatment was significantly less effective in RAS mutant tumors compared to wild-type tumors, with a notable interaction effect (wt: HR = 0.78 vs. mut: HR = 0.91) (Table 2).”
§ RAS Mutations in Advanced Colorectal Cancer: Mechanisms, Clinical Implications, and Novel Therapeutic Approaches > 1. Introduction > 1.3. Differential Benefits of Single-Agent Bevacizumab Maintenance Therapy: Subgroup Analysis Insights
What the sources say
- Supportedcites [41] Stahler, 2020, Current treatment options in RAS mutant metastatic colorectal cancer patients: A meta-analysis of 14 randomized phase III trials, J. Cancer Res. Clin. Oncol. source
The Results section, under ‘Efficacy analysis in RAS WT vs. MUT tumors across all treatment lines,’ states that adding anti-angiogenic treatment was significantly less effective for overall survival in RAS-mutant than in wild-type tumors. It reports the claimed hazard ratios (WT 0.78; MUT 0.91) and a significant interaction (p = 0.039). (LLM, conf=0.95)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
75 more claims · 7 with their cited sources checked
Create a free account to see all 149 claims and to verify the 123 references still open.
- It may state two separate claims as one. 66
- Probably not a substantial claim. 4
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Mutations in RAS, importantly, the KRAS-mutated tumors, are associated with around forty percent of CRCs [12,18,19], while NRAS is less frequent but remains a clinically relevant contributor to tumor heterogeneity.”
From Overcoming Resistance to Anti-EGFR Therapies: Mechanisms of Cetuximab and Panitumumab Resistance and Emerging Combination Strategies (2026) · cites this paper as [19]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ RAS Mutations in Advanced Colorectal Cancer: Mechanisms, Clinical Implications, and Novel Therapeutic Approaches > 1. Introduction > 1.2. Prognostic and Predictive Role of RAS Mutation in Patients Diagnosed with mCRC
“In the ECOG 3200 study, the addition of bevacizumab to chemotherapy, specifically FOLFOX 4 and chemotherapy alone, demonstrated significantly prolonged mOS and mPFS compared to the control groups [31,32].”
§ RAS Mutations in Advanced Colorectal Cancer: Mechanisms, Clinical Implications, and Novel Therapeutic Approaches > References
“Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ RAS Mutations in Advanced Colorectal Cancer: Mechanisms, Clinical Implications, and Novel Therapeutic Approaches > 1. Introduction > 1.9. Immunotherapy
“In the phase II clinical trial Keynote-016, pembrolizumab treatment achieved a 40% objective response rate in patients diagnosed with MSI mCRC who have progression under standard treatments [83].”
§ RAS Mutations in Advanced Colorectal Cancer: Mechanisms, Clinical Implications, and Novel Therapeutic Approaches > References
“Phase 3, open-label, randomized study of first-line pembrolizumab (pembro) vs. investigator-choice chemotherapy for mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) metastatic colorectal carcinoma (mCRC): KEYNOTE-177”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ RAS Mutations in Advanced Colorectal Cancer: Mechanisms, Clinical Implications, and Novel Therapeutic Approaches > 1. Introduction > 1.5. Trifluridine/Tipiracil Plus Bevacizumab
“In FRESCO-2, OS benefit was observed regardless of RAS mutation status, with HRs of 0.66 in RAS WT patients and 0.68 in RAS-mutant patients [50,51].”
§ RAS Mutations in Advanced Colorectal Cancer: Mechanisms, Clinical Implications, and Novel Therapeutic Approaches > References
“Regorafenib plus nivolumab in patients with advanced gastric or colorectal cancer: An open-label, dose-escalation, and dose-expansion phase Ib trial (REGONIVO, EPOC1603)”
Citations
Cites
K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., O'Callaghan, C. J., Tu, D., Tebbutt, N. C., Simes, R. J., Chalchal, H., Shapiro, J. D., Robitaille, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804385 · Cited by 3,622
Grothey, A., Cutsem, E. V., Sobrero, A., Siena, S., Falcone, A., Ychou, M., Humblet, Y., Bouché, O., Mineur, L., Barone, C., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61900-x · Cited by 2,895 · cited 2×
“The CORRECT study, which evaluated 760 patients (255 placebo vs. 505 regorafenib), demonstrated the superiority of rego-rafenib in the primary endpoint of overall survival at 6.4 months vs. 5.0 months (HR) 0.77 (95% CI 0.64–0.94 p = 0.0052) [42].”
InfluentialOverman, M. J., McDermott, R., Leach, J. L., Lonardi, S., Lenz, H.-J., Morse, M. A., Desai, J., Hill, A., Axelson, M., Moss, R. A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30422-9 · Cited by 2,836
Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
Douillard, J.-Y., Oliner, K. S., Siena, S., Tabernero, J., Burkes, R., Barugel, M., Humblet, Y., Bodoky, G., Cunningham, D., Jassem, J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305275 · Cited by 2,263
KRAS Mutation Status Is Predictive of Response to Cetuximab Therapy in Colorectal Cancer
Lièvre, A., Bachet, J.-B., Le Corre, D., Boige, V., Landi, B., Emile, J.-F., Côté, J.-F., Tomasic, G., Penna, C., Ducreux, M., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0191 · Cited by 2,229
Heinemann, V., von Weikersthal, L. F., Decker, T., Kiani, A., Vehling-Kaiser, U., Al-Batran, S.-E., Heintges, T., Lerchenmüller, C., Kahl, C., Seipelt, G., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70330-4 · Cited by 1,740
KRAS G12C Inhibition with Sotorasib in Advanced Solid Tumors
Hong, D. S., Fakih, M. G., Strickler, J. H., Desai, J., Durm, G. A., Shapiro, G. I., Falchook, G. S., Price, T. J., Sacher, A., Denlinger, C. S., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1917239 · Cited by 1,733
Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer
Mayer, R. J., Van Cutsem, E., Falcone, A., Yoshino, T., Garcia-Carbonero, R., Mizunuma, N., Yamazaki, K., Shimada, Y., Tabernero, J., Komatsu, Y., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414325 · Cited by 1,431
T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer
Tran, E., Robbins, P. F., Lu, Y.-C., Prickett, T. D., Gartner, J. J., Jia, L., Pasetto, A., Zheng, Z., Ray, S., Groh, E. M., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1609279 · Cited by 1,368
The MAPK signalling pathways and colorectal cancer
Fang, J. Y., & Richardson, B. C. (2005) · The Lancet Oncology · doi:10.1016/s1470-2045(05)70168-6 · Cited by 1,185 · cited 1×
“Additionally, targeting the Janus kinase/signal transducer and activator of transcription (JAK/STAT) and phosphatidylinositol-3 kinase (PI3K), which affect the MAPK pathway, has been explored in the treatment of colon cancer [64].”
Cited by
Kamel, E. M., Khadrawy, S. M., Ali, M. A. M., Abukhadra, M. R., Yassin, N. Y. S., Alkhedhairi, S., Alkhayl, F. F. A., & Lamsabhi, A. M. (2026) · Frontiers in Chemistry · doi:10.3389/fchem.2026.1808601 · Cited by 3
Diaz, F. C., Waldrup, B., Carranza, F., Manjarrez, S., & Velazquez-Villarreal, E. I. (2026) · Cancers · doi:10.3390/cancers18020239 · Cited by 2
Henrykowska, G., Bartusik-Aebisher, D., Dynarowicz, K., Ramesh, T. S., Smolak, B., & Aebisher, D. (2026) · Pharmaceuticals · doi:10.3390/ph19071041 · Cited by 1
Effects of Tyrphostin A9 and Structurally Related Tyrphostins on Colorectal Carcinoma Cells
Tahtamouni, L. H., Almasri, A. Y., Hamad, M. A., Hussein, N. E., Saleh, K. M., Yasin, S. R., Schobert, R., & Biersack, B. (2025) · Future Pharmacology · doi:10.3390/futurepharmacol5040057 · Cited by 1
Shen, J., Ma, Y., Wang, Y., Yang, M., Liang, T., & Guo, L. (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.118184 · Cited by 1
Metadata
- Authors
- Sütcüoğlu, O., Yıldırım, H. Ç., Almuradova, E., Günenç, D., & Yalçın, Ş.
- Affiliations
- Department of Medical Oncology, Gazi University, Ankara 06560, Turkey
- Department of Medical Oncology, Niğde Research and Training Hospital, Niğde 51100, Turkey
- Department of Medical Oncology, Medicana International İzmir Hospital, İzmir 35170, Turkey
- Ege University (TR)
- Hacettepe University (TR)
- Venue
- Medicina
- Publisher
- MDPI AG
- Published
- 2025-06-30
- Volume
- 61
- Issue
- 7
- Pages
- 1202
- ISSN
- 1010-660X (ISSN-L)
- 1648-9144
- PMC
- PMC12299888
- OpenAlex
- W4411902113
- Semantic Scholar
- 462e15cd6a754c3946344410b05543b29153cfa7
- Cited by
- 10
- References
- 110
- Citations by year
- 2026: 7 · 2025: 3
- FWCI
- 1.17
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Medicina (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Keywords
- RAS mutations, KRAS, NRAS, metastatic colorectal cancer, KRAS G12C inhibitors, sotorasib, adagrasib, treatment resistance, targeted therapy, personalized cancer management
- MeSH terms
- Antineoplastic Agents, Humans, Membrane Proteins, Mutation, Colorectal Neoplasms, Proto-Oncogene Proteins p21(ras), GTP Phosphohydrolases, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-06, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-06 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: RAS Mutations in Advanced Colorectal Cancer: Mechanisms, Clinical Implications, and Novel Therapeutic Approaches. https://app.cochat.ai/papers/10.3390/medicina61071202
- The paper
- Sütcüoğlu, O., Yıldırım, H. Ç., Almuradova, E., Günenç, D., & Yalçın, Ş. (2025). RAS Mutations in Advanced Colorectal Cancer: Mechanisms, Clinical Implications, and Novel Therapeutic Approaches. Medicina. https://doi.org/10.3390/medicina61071202
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.